Risk factors
Intellia Therapeutics (NTLA) risk factors
Item 1A of every Intellia Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors75 risks3 new8 dropped18 reworded
Intellia highlights ongoing clinical trials for nex-z and lonvo-z, mentioning a clinical hold on the MAGNITUDE trial IND for nex-z.
Filed Feb 26, 2026 - FY2024 10-K risk factors80 risks
Intellia Therapeutics faces heavy risks from its unproven CRISPR/Cas9 in vivo and ex vivo genome editing technologies, substantial ongoing financial losses of $519.0 million for 2024, and complex third-party intellectual property and manufacturing dependencies.
Filed Feb 27, 2025